Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population-Reference-Cited by-同舟云学术

Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population

Published:2019-08 Issue: Volume:41 Page:69-78
ISSN:1092-9134
Container-title:Annals of Diagnostic Pathology
language:en
Short-container-title:Annals of Diagnostic Pathology

Author:

Zengin Mehmet^ORCID

Funder

Kırıkkale University

Publisher

Elsevier BV

Subject

General Medicine,Pathology and Forensic Medicine

Reference37 articles.

1. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Labianca;Ann Oncol,2013

2. Colorectal cancer;Cunningham;Lancet,2010

3. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study;Gray;Lancet,2007

4. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features;O'Connor;J Clin Oncol,2001

5. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer;Benson;J Clin Oncol,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of tumor‐infiltrating immune cells in clinical early‐stage oral squamous cell carcinoma;Journal of Oral Pathology & Medicine;2022-10-05

2. Tumour infiltrating lymphocytes in colorectal cancers- correlation with tumour biology and clinical outcome- a cohort study;Journal of the Pakistan Medical Association;2022-08-16

3. Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity;Proceedings of the National Academy of Sciences;2021-02-24

4. PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer;Cellular Oncology;2021-01-19

5. The role of cancer-related inflammation for prediction of poor survival in postmenopausal female patients with stage II/III colon cancer;International Immunopharmacology;2020-08